2014;9:e99286 Oliver EA, Schwartz L, Warren LH
This article explains what biomarkers can optionally be monitored on GLP-1 therapy and why, who might benefit from testing versus who likely does not need it, what baseline and ongoing monitoring might involve if you choose to do it, and how to decide what makes sense for your situation
Tirzepatide users maintain losses more successfully because the hormone-mimicking mechanism continues to regulate appetite, not willpower alone
Importantly, the trial also demonstrated a reduction in all-cause mortality , making Victoza one of the first glucose-lowering medications shown to extend life expectancy in this population
The opportunity now is to be ready with accurate, balanced information before the demand arrives
While Eli Lilly and Company includes warning labels about common side effects of their dulaglutide medication, the language on the label may not have provided adequate warnings about severe health risks such as stomach paralysis, intestinal blockages, bowel obstruction, or frequent and excessive vomiting